From the Research
NAD (Nicotinamide Adenine Dinucleotide) is not currently recognized as an established treatment for COVID-19, and patients should rely on proven treatments such as antiviral medications, monoclonal antibodies, and supportive care, as recommended by established medical guidelines. NAD is a coenzyme found in all living cells that plays a crucial role in metabolism, particularly in energy production and cellular repair processes. It exists in two forms: NAD+ (oxidized) and NADH (reduced). While some researchers have hypothesized that NAD+ supplementation might help with COVID-19 by potentially supporting immune function and reducing inflammation, there is insufficient clinical evidence to support its use as a treatment 1, 2, 3, 4, 5.
Current Treatments for COVID-19
The primary treatments for COVID-19 include:
- Antiviral medications, such as remdesivir, which has been shown to improve survival and disease progression in various patient populations with COVID-19 4, 5
- Monoclonal antibodies, which have been effective in reducing the risk of disease progression in non-hospitalized patients with mild-to-moderate COVID-19 at high risk of disease progression 1
- Supportive care, which depends on disease severity and may include oxygen therapy, mechanical ventilation, and other interventions
Importance of Following Established Medical Guidelines
It is essential for patients with COVID-19 to follow established medical guidelines and consult healthcare providers rather than relying on unproven supplements. The use of unproven treatments, such as NAD+ supplementation, may lead to delays in seeking effective treatment and potentially worsen outcomes.
Key Takeaways
- NAD is not a recognized treatment for COVID-19
- Proven treatments for COVID-19 include antiviral medications, monoclonal antibodies, and supportive care
- Patients should follow established medical guidelines and consult healthcare providers rather than relying on unproven supplements
- The use of remdesivir, in combination with dexamethasone, has been associated with lower mortality risk and improved clinical outcomes in patients hospitalized for COVID-19 4